HUTCHMED (NASDAQ:HCM) Shares Gap Up After Analyst Upgrade

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) gapped up prior to trading on Thursday after Daiwa Securities Group upgraded the stock from a hold rating to a buy rating. The stock had previously closed at $12.04, but opened at $13.60. HUTCHMED shares last traded at $13.7280, with a volume of 145,382 shares.

Other research analysts have also recently issued research reports about the company. Bank of America dropped their price objective on HUTCHMED from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Morgan Stanley set a $13.60 price target on shares of HUTCHMED in a report on Thursday, May 28th. Wall Street Zen upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. The Goldman Sachs Group cut their price objective on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, July 23rd. Finally, Weiss Ratings lowered HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $14.87.

Key Stories Impacting HUTCHMED

Here are the key news stories impacting HUTCHMED this week:

• Positive Sentiment: HUTCHMED granted GSK exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate for solid tumors. The deal includes a $110 million upfront payment and could generate up to $1.295 billion in total milestone payments, plus royalties. Reuters article
• Positive Sentiment: The partnership validates HUTCHMED’s oncology pipeline through a major global pharmaceutical partner and could provide funding and development support for HMPL-A830. The drug is expected to enter clinical trials in the second half of 2026. HUTCHMED announcement
• Positive Sentiment: Daiwa Securities upgraded HCM from “hold” to “buy.” Panmure and Cavendish also reiterated “buy” ratings, citing the GSK deal and what they view as an overlooked valuation relative to HUTCHMED’s expanding oncology pipeline. Broker responses
• Neutral Sentiment: Management discussed the strategic partnership and licensing arrangement in an investor transcript, providing additional details on HMPL-A830’s development and the collaboration with GSK. Seeking Alpha transcript
• Negative Sentiment: HMPL-A830 remains an experimental therapy, so the milestone value is contingent on successful clinical development, regulatory approvals and commercialization. Investors may therefore continue to weigh substantial drug-development risk despite the sizable headline deal.

Institutional Investors Weigh In On HUTCHMED

Several institutional investors have recently bought and sold shares of HCM. Ameriprise Financial Inc. grew its holdings in HUTCHMED by 4.7% in the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after purchasing an additional 698 shares during the last quarter. Bank of America Corp DE boosted its position in shares of HUTCHMED by 5.9% in the 3rd quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock worth $343,000 after purchasing an additional 1,209 shares in the last quarter. Crossmark Global Holdings Inc. boosted its position in shares of HUTCHMED by 3.3% in the 4th quarter. Crossmark Global Holdings Inc. now owns 52,476 shares of the company’s stock worth $700,000 after purchasing an additional 1,680 shares in the last quarter. State Street Corp grew its stake in HUTCHMED by 1.2% during the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after buying an additional 3,801 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in HUTCHMED by 3.0% during the 4th quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $1,798,000 after buying an additional 3,900 shares in the last quarter. 8.82% of the stock is currently owned by institutional investors and hedge funds.

HUTCHMED Trading Down 0.1%

The company has a 50-day moving average of $11.76 and a 200-day moving average of $12.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64.

HUTCHMED (NASDAQ:HCM) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The firm had revenue of $139.14 million during the quarter, compared to analyst estimates of $304.16 million. Research analysts expect that HUTCHMED will post 0.33 EPS for the current fiscal year.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.